[go: up one dir, main page]

WO2018104766A1 - Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2 - Google Patents

Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2 Download PDF

Info

Publication number
WO2018104766A1
WO2018104766A1 PCT/IB2016/057387 IB2016057387W WO2018104766A1 WO 2018104766 A1 WO2018104766 A1 WO 2018104766A1 IB 2016057387 W IB2016057387 W IB 2016057387W WO 2018104766 A1 WO2018104766 A1 WO 2018104766A1
Authority
WO
WIPO (PCT)
Prior art keywords
dimethyl
dihydro
inden
mmol
benzotriazol
Prior art date
Application number
PCT/IB2016/057387
Other languages
English (en)
Inventor
Jeffrey Charles Boehm
James Francis Callahan
Thomas Daniel Heightman
Jeffrey K. Kerns
Alison Jo-Anne Woolford
Hongxing Yan
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Astex Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited, Astex Therapeutics Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Priority to CN201680083119.7A priority Critical patent/CN108779108A/zh
Priority to KR1020187017624A priority patent/KR20190088404A/ko
Priority to PCT/IB2016/057387 priority patent/WO2018104766A1/fr
Publication of WO2018104766A1 publication Critical patent/WO2018104766A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to aryl analogs, pharmaceutical compositions containing
  • NRF2 NF-E2 related factor 2
  • CNC cap-n-collar
  • NRF2 levels are tightly controlled by the cytosolic actin-bound repressor, KEAP1
  • DJ1 oxidative stress, DJ1 (PARK7) is activated and stabilizes NRF2 protein by preventing NRF2
  • COPD chronic obstructive pulmonary disease
  • NRF2 modulators may treat
  • asthma and pulmonary fibrosis include asthma and pulmonary fibrosis (Cho, H.Y., and Kleeberger, S.R.2010, Toxicol. Appl.
  • MARCO Collagenous structure
  • the therapeutic potential of targeting NRF2 in the lung is not limited to COPD. Rather, targeting the NRF2 pathway could provide treatments for other human lung and respiratory diseases that exhibit oxidative stress components such as chronic and acute asthma, lung disease secondary to environmental exposures including but not limited to ozone, diesel exhaust and occupational exposures, fibrosis, acute lung infection (e.g., viral (Noah, T.L. et al. 2014. PLoS ONE 9(6): e98671), bacterial or fungal), chronic lung infection, ⁇ 1 antitrypsin disease, and cystic fibrosis (CF, Chen, J. et al.2008. PLoS One, 2008;3(10):e3367).
  • oxidative stress components such as chronic and acute asthma, lung disease secondary to environmental exposures including but not limited to ozone, diesel exhaust and occupational exposures, fibrosis, acute lung infection (e.g., viral (Noah, T.L. et al. 2014. PLoS ONE 9(6): e
  • a therapy that targets the NRF2 pathway also has many potential uses outside the lung and respiratory system. Many of the diseases for which an NRF2 activator may be useful are autoimmune diseases (psoriasis, IBD, MS), suggesting that an NRF2 activator may be useful in autoimmune diseases in general.
  • autoimmune diseases psoriasis, IBD, MS
  • a drug activating the NRF2 pathway could also be useful for treatment of several neurodegenerative diseases including Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) (Brain Res.2012 Mar 29;1446:109-18.2011.12.064. Epub 2012 Jan 12.) and multiple sclerosis (MS).
  • PD Parkinson’s disease
  • AD Alzheimer’s disease
  • ALS amyotrophic lateral sclerosis
  • MS multiple sclerosis
  • tBHQ tert-butylhydroquinone
  • NRF2 may also help treat cases of Friedreich’s Ataxia, where increased sensitivity to oxidative stress and impaired NRF2 activation has been reported (Paupe V., et al, 2009. PLoS One; 4(1):e4253.
  • Age-related macular degeneration is a common cause of vision loss in people over the age of 50. Cigarette smoking is a major risk factor for the development of non- neovascular (dry) AMD and perhaps also neovascular (wet) AMD. Findings in vitro and in preclinical species support the notion that the NRF2 pathway is involved in the anti-oxidant response of retinal epithelial cells and modulation of inflammation in pre-clinical models of eye injury (Schimel, et al. 2011. Am. J. Pathol.178:2032-2043). Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive, blinding disease characterized by corneal endothelial cells apoptosis.
  • FECD Fuchs Endothelial Corneal Dystrophy
  • NRF2 activator may be useful in uveitis or other inflammatory eye conditions.
  • Non-alcoholic steatohepatitis is a disease of fat deposition, inflammation, and damage in the liver that occurs in patients who drink little or no alcohol.
  • NASH Non-alcoholic steatohepatitis
  • KO mice lacking NRF2 when challenged with a methionine- and choline-deficient diet
  • NRF2 activators oltipraz and NK-252 in rats on a choline-deficient L- amino acid-defined diet significantly attenuated progression of histologic abnormalities, especially hepatic fibrosis (Shimozono R.
  • liver diseases that may be amenable to NRF2 modulation are toxin-induced liver disease (e.g., acetaminophen-induced hepatic disease), viral hepatitis, and cirrhosis (Oxidative Medicine and Cellular Longevity Volume 2013 (2013), Article ID 763257, 9 page).
  • toxin-induced liver disease e.g., acetaminophen-induced hepatic disease
  • viral hepatitis e.g., cirrhosis
  • this invention provides for aryl analogs, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them.
  • this invention provides for the use of the compounds of Formulas (I) and (II) as NRF2 regulators.
  • this invention provides for the use of the compounds of Formulas (I) and (II) for treating and preventing conditions associated with NRF2 imbalance.
  • the invention is provides a pharmaceutical composition comprising a compound of the invention according to Formulas (I) and (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • this invention is directed to a pharmaceutical composition for the treatment of an NRF2 regulated disease or disorder, wherein the composition comprises a compound according to Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
  • this invention provides for a method of treating respiratory and non- respiratory disorders, including COPD, asthma, fibrosis, chronic and acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, ⁇ 1 antitrypsin disease, cystic fibrosis, autoimmune diseases, diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation, Pulmonary Arterial Hypertension,
  • Atherosclerosis hypertension, heart failure, Parkinson’s disease (PD), Alzheimer’s disease (AD), Friedreich’s Ataxia (FA), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), inflammatory bowel disease, colon cancer, neovascular (dry) AMD and neovascular (wet) AMD, eye injury, Fuchs Endothelial Corneal Dystrophy (FECD), uveitis or other inflammatory eye conditions, Non-alcoholic Steatohepatitis (NASH), toxin-induced liver disease (e.g.,
  • this invention provides for the use of the compounds of Formulas (I) and (II) for the treatment of respiratory and non-respiratory disorders, including COPD, asthma, fibrosis, chronic and acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, ⁇ 1 antitrypsin disease, cystic fibrosis, autoimmune diseases, diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation, Pulmonary Arterial Hypertension, atherosclerosis, hypertension, heart failure, Parkinson’s disease (PD), Alzheimer’s disease (AD), Friedreich’s Ataxia (FA), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), inflammatory bowel disease, colon cancer, neovascular (dry) AMD and neovascular (wet) AMD, eye injury, Fuchs Endothelial Corneal Dystrophy (FECD), uveitis or other respiratory and non-re
  • this invention relates to use of a compound of Formulas (I) and (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of respiratory and non-respiratory disorders, including COPD, asthma, fibrosis, chronic and acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, ⁇ 1 antitrypsin disease, cystic fibrosis, autoimmune diseases, diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation, Pulmonary Arterial Hypertension, atherosclerosis, hypertension, heart failure, Parkinson’s disease (PD),
  • COPD chronic lung infection
  • ⁇ 1 antitrypsin disease cystic fibrosis
  • autoimmune diseases diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation
  • Pulmonary Arterial Hypertension atherosclerosis, hypertension,
  • AD Alzheimer’s disease
  • FA amyotrophic lateral sclerosis
  • MS multiple sclerosis
  • inflammatory bowel disease colon cancer
  • neovascular (dry) AMD and neovascular (wet) AMD eye injury
  • Fuchs Endothelial Corneal Dystrophy FECD
  • uveitis or other inflammatory eye conditions Non-alcoholic Steatohepatitis (NASH), toxin-induced liver disease (e.g., acetaminophen-induced hepatic disease), viral hepatitis, cirrhosis, psoriasis, dermatitis/topical effects of radiation, immunosuppression due to radiation exposure,
  • NASH Non-alcoholic Steatohepatitis
  • toxin-induced liver disease e.g., acetaminophen-induced hepatic disease
  • viral hepatitis cirrhosis
  • psoriasis dermatitis/topical effects of radiation
  • this invention relates to a compound of Formulas (I) and (II) or a pharmaceutically acceptable salt thereof, for use in medical therapy.
  • this invention relates to a compound of Formulas (I) and (II) or a pharmaceutically acceptable salt thereof, for use in the treatment of respiratory and non- respiratory disorders, including COPD, asthma, fibrosis, chronic and acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, ⁇ 1 antitrypsin disease, cystic fibrosis, autoimmune diseases, diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation, Pulmonary Arterial Hypertension,
  • Atherosclerosis hypertension, heart failure, Parkinson’s disease (PD), Alzheimer’s disease (AD), Friedreich’s Ataxia (FA), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), inflammatory bowel disease, colon cancer, neovascular (dry) AMD and neovascular (wet) AMD, eye injury, Fuchs Endothelial Corneal Dystrophy (FECD), uveitis or other inflammatory eye conditions, Non-alcoholic Steatohepatitis (NASH), toxin-induced liver disease (e.g.,
  • acetaminophen-induced hepatic disease acetaminophen-induced hepatic disease
  • viral hepatitis cirrhosis
  • psoriasis psoriasis
  • dermatitis/topical effects of radiation immunosuppression due to radiation exposure
  • Preeclampsia and high altitude sickness.
  • this invention relates to the use of a compound of Formula (I) or Formula (II) for the treatment of COPD.
  • this invention relates to use of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of COPD.
  • this invention relates to a compound of Formulas (I) and (II) or a pharmaceutically acceptable salt thereof, for use in the treatment COPD.
  • this invention relates to a method of treating COPD which comprises administering to a human in need thereof, a compound of Formula (I) or Formula (II).
  • this invention relates to the use of a compound of Formula (I) or Formula (II) for the treatment of heart failure.
  • this invention relates to a method of treating heart failure which comprises administering to a human in need thereof, a compound of Formula (I) or Formula (II).
  • this invention relates to use of a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of heart failure.
  • this invention relates to a compound of Formula (I) or Formula (II) or a pharmaceutically acceptable salt thereof, for use in the treatment of heart failure.
  • the compounds of Formulas (I) and (II) and pharmaceutically acceptable salts thereof may be used in combination with one or more other agents which may be useful in the prevention or treatment of allergic disease, inflammatory disease, autoimmune disease, for example; antigen immunotherapy, anti-histamines, corticosteroids, (e.g., fluticasone propionate, fluticasone furoate, beclomethasone dipropionate, budesonide, ciclesonide, mometasone furoate, triamcinolone, flunisolide), NSAIDs, leukotriene modulators (e.g., montelukast, zafirlukast, pranlukast), iNOS inhibitors, tryptase inhibitors, IKK2 inhibitors, p38 inhibitors, Syk inhibitors, protease inhibitors such as elastase inhibitors, integrin antagonists (e.g., beta-2 integrin antagonists), adenos
  • bronchodilators e.g., muscarinic antagonists, beta-2 agonists
  • methotrexate and similar agents
  • monoclonal antibody therapy such as anti-IgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1 and similar agents
  • cytokine receptor therapies e.g.
  • antigen non-specific immunotherapies e.g. interferon or other cytokines/chemokines, chemokine receptor modulators such as CCR3, CCR4 or CXCR2 antagonists, other cytokine/chemokine agonists or antagonists, TLR agonists and similar agents.
  • the compounds may also be used in combination with agents for aiding transplantation including Cyclosporines, Tacrolimus, Mycophenolate mofetil, Prednisone, Azathioprine , Sirolimus, Daclizumab, Basiliximab, or OKT3.
  • agents for aiding transplantation including Cyclosporines, Tacrolimus, Mycophenolate mofetil, Prednisone, Azathioprine , Sirolimus, Daclizumab, Basiliximab, or OKT3.
  • diabetes may also be used in combination with agents for Diabetes: metformin (biguanides), meglitinides, sulfonylureas, DPP-4 inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Amylin mimetics, Incretin mimetics, and insulin.
  • metformin biguanides
  • meglitinides meglitinides
  • sulfonylureas DPP-4 inhibitors
  • Thiazolidinediones Thiazolidinediones
  • Alpha-glucosidase inhibitors Amylin mimetics
  • Incretin mimetics and insulin.
  • the compounds may be used in combination with antihypertensives such as diuretics, ACE inhibitors, ARBS, calcium channel blockers, and beta blockers.
  • antihypertensives such as diuretics, ACE inhibitors, ARBS, calcium channel blockers, and beta blockers.
  • the invention is directed to the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, as an active therapeutic substance. More specifically, this invention provides for the use of the compounds described herein for the treatment of a respiratory and non-respiratory disorder, specifically, a disease or disorder recited herein. Accordingly, the invention provides for the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, as an active therapeutic substance in the treatment of a human in need thereof with a respiratory and non-respiratory disorder, specifically, a disease or disorder recited herein. Specifically, the invention provides for the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, as an active therapeutic substance in the treatment of COPD.
  • the invention is directed to a compound described herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of a respiratory and non-respiratory disorder, for example the diseases and disorders recited herein.
  • the invention further provides for the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a respiratory and non-respiratory disorder, for example the diseases and disorders recited herein.
  • the invention further provides for the use of a compound of Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of COPD.
  • B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1- 3 alkyl, -O- C 1-3 alkyl, CN, -(CH 2 ) 2 –O–(CH 2 ) 2 -OR 4 and halo;
  • D is–C(O)OH, -C(O)NHSO 2 CH 3 ,–SO 2 NHC(O)CH 3 , 5-(trifluoromethyl)-4H-1,2,4-triazol- 2-yl, or tetrazolyl;
  • R 1 is independently hydrogen, C 1-3 alkyl, F, C 3-6 spirocycloalkyl, oxetane, or the two R 1 groups together with the carbon to which they are attached form a cyclopropyl group;
  • R 4 is hydrogen or C 1-3 alkyl;
  • A is tetrahydrobenzoxazepinyl, tetrahydrobenzazepinyl, tetrahydroimidazodiazepinyl, or tetrahydro-pyrido-oxazepinyl, all of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C 1-3 alkyl, halo, CN, -OC 1-3 alkyl, -CH 2 -O-CH 3 , C 3-6 spirocycloalkyl, and OH;
  • n 1 or 2;
  • B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl, -O- C 1-3 alkyl, CN, -(CH 2 ) 2 –O–(CH 2 ) 2 -OR 4 and halo;
  • D is–C(O)OH, -C(O)NHSO 2 CH 3 ,–SO 2 NHC(O)CH 3 , 5-(trifluoromethyl)-4H-1,2,4-triazol-2-yl, or tetrazolyl;
  • R 1 is independently hydrogen, C 1-3 alkyl, F, C 3-6 spirocycloalkyl, oxetane, or the two R 1 groups together with the carbon to which they are attached form a cyclopropyl group;
  • R 4 is hydrogen or -C 1-3 alkyl
  • Linker is—CH 2 , -O-C(O)-, -CH 2 -C(O)-,–C(O)-, -CH(CH 3 )-C(O)-, or–N(CH 3 )-C(O)-;
  • A is cyclohexyl, cyclopentyl, phenyl or decahydronapthalenyl; all of which may be unsubstituted or independently substituted by C 1-3 alkyl, CN, and halo;
  • A is C 4-5 alkyl which may be substituted by -OC 1-3 alkyl;
  • n 1 or 2;
  • X is CH 2 or O
  • Alkyl refers to a monovalent saturated hydrocarbon chain having the specified number of carbon member atoms.
  • C 1-4 alkyl refers to an alkyl group having from 1 to 4 carbon member atoms.
  • Alkyl groups may be straight or branched. Representative branched alkyl groups have one, two, or three branches.
  • Alkyl includes methyl, ethyl, propyl, (n-propyl and isopropyl), and butyl (n-butyl, isobutyl, s-butyl, and t-butyl).
  • C 3-6 spirocycloalkyl refers to spiro-cyclopropyl, spiro-cyclobutyl, spiro-cyclopentane and spiro-cyclohexane.
  • the terms 'halogen' and 'halo' include fluorine, chlorine, bromine and iodine, and fluoro, chloro, bromo, and iodo, respectively.
  • Substituted in reference to a group indicates that one or more hydrogen atom attached to a member atom within the group is replaced with a substituent selected from the group of defined substituents. It should be understood that the term “substituted” includes the implicit provision that such substitution be in accordance with the permitted valence of the substituted atom and the substituent and that the substitution results in a stable compound (i.e. one that does not spontaneously undergo transformation such as by rearrangement, cyclization, or elimination and that is sufficiently robust to survive isolation from a reaction mixture). When it is stated that a group may contain one or more substituents, one or more (as appropriate) member atoms within the group may be substituted. In addition, a single member atom within the group may be substituted with more than one substituent as long as such substitution is in accordance with the permitted valence of the atom. Suitable substituents are defined herein for each substituted or optionally substituted group.
  • the invention also includes various isomers of the compounds of Formulas (I) and (II) and mixtures thereof.“Isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers).
  • the compounds according to Formula (I) or Formula (II) contain one or more asymmetric centers, also referred to as chiral centers, and may, therefore, exist as individual enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. All such isomeric forms are included within the present invention, including mixtures thereof.
  • Chiral centers may also be present in a substituent such as an alkyl group. Wherethe stereochemistry of a chiral center present in Formulas (I) and (II) , or in any chemical structure illustrated herein, is not specified the structure is intended to encompass any stereoisomer and all mixtures thereof. Thus, compounds according to Formulas (I) and (II) containing one or more chiral centers may be used as racemic mixtures, enantiomerically enriched mixtures, or as enantiomerically pure individual stereoisomers.
  • Individual stereoisomers of a compound according to Formulas (I) and (II) which contain one or more asymmetric centers may be resolved by methods known to those skilled in the art. For example, such resolution may be carried out (1) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
  • stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.
  • “pharmaceutically acceptable” refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts of the compounds according to Formulas (I) and (II) may be prepared. These pharmaceutically acceptable salts may be prepared in situ during the final isolation and purification of the compound, or by separately treating the purified compound in its free acid or free base form with a suitable base or acid, respectively.
  • compounds according to Formulas (I) and (II) may contain an acidic functional group and are, therefore, capable of forming pharmaceutically acceptable base addition salts by treatment with a suitable base.
  • bases include a) hydroxides, carbonates, and bicarbonates of sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc; and b) primary, secondary, and tertiary amines including aliphatic amines, aromatic amines, aliphatic diamines, and hydroxy alkylamines such as methylamine, ethylamine, 2- hydroxyethylamine, diethylamine, triethylamine, ethylenediamine, ethanolamine,
  • compounds according to Formulas (I) and (II) may contain a basic functional group and are therefore capable of forming pharmaceutically acceptable acid addition salts by treatment with a suitable acid.
  • suitable acids include pharmaceutically acceptable inorganic acids and organic acids.
  • Representative pharmaceutically acceptable acids include hydrogen chloride, hydrogen bromide, nitric acid, sulfuric acid, sulfonic acid, phosphoric acid, acetic acid, hydroxyacetic acid, phenylacetic acid, propionic acid, butyric acid, valeric acid, maleic acid, acrylic acid, fumaric acid, succinic acid, malic acid, malonic acid, tartaric acid, citric acid, salicylic acid, benzoic acid, tannic acid, formic acid, stearic acid, lactic acid, ascorbic acid, methylsulfonic acid, p-toluenesulfonic acid, oleic acid, lauric acid, and the like.
  • the term“a compound of Formula (I) or (II)” or“the compound of Formula (I) or (II)” refers to one or more compounds according to Formula (I) or (II).
  • the compound of Formula (I) or (II) may exist in solid or liquid form. In the solid state, it may exist in crystalline or noncrystalline form, or as a mixture thereof.
  • pharmaceutically acceptable solvates may be formed from crystalline compounds wherein solvent molecules are incorporated into the crystalline lattice during crystallization.
  • Solvates may involve non-aqueous solvents such as, but not limited to, ethanol, isopropanol, DMSO, acetic acid, ethanolamine, or ethyl acetate, or they may involve water as the solvent that is incorporated into the crystalline lattice. Solvates wherein water is the solvent incorporated into the crystalline lattice are typically referred to as "hydrates.” Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. The invention includes all such solvates.
  • polymorphs may exhibit polymorphism (i.e. the capacity to occur in different crystalline structures). These different crystalline forms are typically known as "polymorphs.”
  • the invention includes all such polymorphs. Polymorphs have the same chemical composition but differ in packing, geometrical arrangement, and other descriptive properties of the crystalline solid state. Polymorphs, therefore, may have different physical properties such as shape, density, hardness, deformability, stability, and dissolution properties. Polymorphs typically exhibit different melting points, IR spectra, and X-ray powder diffraction patterns, which may be used for identification.
  • polymorphs may be produced, for example, by changing or adjusting the reaction conditions or reagents, used in making the compound. For example, changes in temperature, pressure, or solvent may result in polymorphs. In addition, one polymorph may spontaneously convert to another polymorph under certain conditions.
  • the subject invention also includes isotopically-labelled compounds, which are identical to those recited in Formulas (I) and (II) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, fluorine, iodine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I and 125 I.
  • Isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
  • 11 C and 18 F isotopes are particularly useful in PET (positron emission tomography), and 125 I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging.
  • substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • Isotopically labeled compounds of Formulas (I) and (II) and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl, -O- C 1-3 alkyl, CN, -(CH 2 ) 2 –O–(CH 2 ) 2 -OR 4 and halo;
  • D is–C(O)OH, -C(O)NHSO 2 CH 3 ,–SO 2 NHC(O)CH 3 , 5-(trifluoromethyl)-4H-1,2,4-triazol- 2-yl, or tetrazolyl;
  • R 1 is independently hydrogen, C 1-3 alkyl, F, C 3-6 spirocycloalkyl, oxetane, or the two R 1 groups together with the carbon to which they are attached form a cyclopropyl group;
  • R 4 is hydrogen or C 1-3 alkyl
  • A is tetrahydrobenzoxazepinyl, tetrahydrobenzazepinyl, tetrahydroimidazodiazepinyl, or tetrahydro-pyrido-oxazepinyl, all of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C 1-3 alkyl, halo, CN, -OC 1-3 alkyl, -CH 2 -O-CH 3 , C 3- 6 spirocycloalkyl, and OH; and
  • n 1 or 2;
  • B is benzotriazolyl or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl and halo;
  • R 1 is independently hydrogen or methyl or the two R1 groups together with the carbon to which they are attached form a cyclopropyl group;
  • A is tetrahydrobenzoxazepinyl, tetrahydrobenzazepinyl, or tetrahydro-pyrido-oxazepinyl, all of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C 1-3 alkyl, halo or CN, or -O C 1-3 alkyl; and
  • n 1 or 2;
  • B is benzotriazolyl or phenyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl, halo and CN;
  • R 1 is independently hydrogen or C 1-3 alkyl
  • A is tetrahydrobenzoxazepinyl, tetrahydrobenzazepinyl, tetrahydroimidazodiazepinyl, or tetrahydro-pyrido-oxazepinyl, all of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from -C 1-3 alkyl, halo, CN, -OC 1-3 alkyl, -CH 2 -O-CH 3 , C 3- 6 spirocycloalkyl, and OH; and
  • n 1;
  • B is benzotriazolyl which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl;
  • R 1 is independently hydrogen or C 1-3 alkyl
  • A is tetrahydrobenzoxazepinyl which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from: -C 1-3 alkyl, -OC 1-3 alkyl, CN and halo; and
  • n 1;
  • B is benzotriazolyl, phenyl, triazolopyridinyl, or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl, -O- C 1-3 alkyl, CN, -(CH 2 ) 2 –O–(CH 2 ) 2 -OR 4 and halo;
  • D is–C(O)OH, -C(O)NHSO 2 CH 3 ,–SO 2 NHC(O)CH 3 , 5-(trifluoromethyl)-4H-1,2,4-triazol- 2-yl, or tetrazolyl;
  • R 1 is independently hydrogen, C 1-3 alkyl, F, C 3-6 spirocycloalkyl, oxetane, or the two R 1 groups together with the carbon to which they are attached form a cyclopropyl group;
  • R 4 is hydrogen or C 1-3 alkyl
  • Linker is–CH 2 -, -O-C(O)-, -CH 2 -C(O)-,–C(O)-, -CH(CH 3 )-C(O)-, or–N(CH 3 )-C(O)-;
  • A is cyclohexyl, cyclopentyl, phenyl or decahydronapthalenyl; all of which may be unsubstituted or substituted independently by C 1-3 alkyl, CN, and halo;
  • A is C 4-5 alkyl which may be substituted by -OC 1-3 alkyl;
  • n 1 or 2;
  • X is CH 2 or O
  • B is benzotriazolyl or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl and halo;
  • R 1 is independently hydrogen or methyl or the two R 1 groups together with the carbon to which they are attached form a cyclopropyl group
  • Linker is—CH 2 -, -O-C(O)-, -CH(CH 3 )-C(O)-, or–N(CH 3 )-C(O)-;
  • A is cyclohexyl or cyclopentyl, each of which may be unsubstituted or independently substituted by C 1-3 alkyl, CN, and halo;
  • n 1;
  • X is CH 2 or O
  • B is benzotriazolyl or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl and -O- C 1-3 alkyl;
  • R 1 is independently hydrogen
  • R 2 is hydrogen
  • Linker is—CH 2 -, -O-C(O)-, -CH 2 -C(O)-;
  • A is cyclohexyl, phenyl or decahydronapthalenyl; all of which may be unsubstituted or independently substituted by C 1-3 alkyl, CN, and halo;
  • A is C 4-5 alkyl which may be substituted by -OC 1-3 alkyl;
  • n 1;
  • X is CH 2 ;
  • B is benzotriazolyl or -(CH 2 ) 2 triazolyl each of which may be unsubstituted or substituted by 1, 2, or 3 substituents independently chosen from–C 1-3 alkyl and -O- C 1-3 alkyl;
  • Linker is—CH 2 -, -O-C(O)-, -CH 2 -C(O)-;
  • A is cyclohexyl, phenyl or decahydronapthalenyl; all of which may be unsubstituted or independently substituted by C 1-3 alkyl, CN, and halo;
  • A is C 4-5 alkyl which may be substituted by -OC 1-3 alkyl;
  • n 1;
  • X is CH 2 or O
  • a substituent described herein is not compatible with the synthetic methods described herein, the substituent may be protected with a suitable protecting group that is stable to the reaction conditions.
  • the protecting group may be removed at a suitable point in the reaction sequence to provide a desired intermediate or target compound.
  • suitable protecting groups and the methods for protecting and de-protecting different substituents using such suitable protecting groups are well known to those skilled in the art; examples of which may be found in T. Greene and P. Wuts, Protecting Groups in Chemical Synthesis (3rd ed.), John Wiley & Sons, NY (1999).
  • a substituent may be specifically selected to be reactive under the reaction conditions used. Under these
  • reaction conditions convert the selected substituent into another substituent that is either useful as an intermediate compound or is a desired substituent in a target compound.
  • Scheme 2 shows a general scheme for the preparation of 5-bromo-7-methoxy-1-methyl- 1H-benzo[d][1,2,3]triazole.
  • methylation of the phenol using K 2 CO 3 and MeI (step a) provides intermediate 2 which can be brominated with NBS (step c).
  • Methylation of the aniline (step d) followed by reduction of the nitro group (step d) and diazotization and cyclization (step e) provide the required triazole 5.
  • Scheme 3 shows a general scheme for the preparation of 5-bromo-7-methoxy-1,4- dimethyl-1H-benzo[d][1,2,3]triazole This two step process starts with iodination at C7 of 5- bromo-1,4-dimethyl-1H-benzo[d][1,2,3]triazole. Copper mediated replacement of the iodide with methanol provides the desired material.
  • Scheme 4 shows a general scheme for the preparation of 6-chloro-3-methyl-3H- [1,2,3]triazolo[4,5-c]pyridine.
  • oxidation provides intermediate 2. This is subsequently converted to nitro intermediate 3.
  • Scheme 5 represents a general scheme for the preparation of 2-ethyl-2,3,4,5- tetrahydrobenzo[f][1,4]oxazepines, and 2,2-dimethyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepines used in the invention.
  • R 7 is -C 1-3 alkyl, halo, CN, -OC 1-3 alkyl, -CH 2 -O-CH 3 , or OH; and R 8 and R 9 are hydrogen, C 1-3 alkyl, or C 3-6 spirocycloalkyl.
  • Scheme 6 represents a general scheme for the preparation of (R)-2-ethyl-2,3,4,5- tetrahydrobenzo[f][1,4]oxazepines, and 2,2-dimethyl-2,3,4,5-tetrahydrobenzo[f][1,4]oxazepines used in the invention.
  • R 7 and R 8 are as defined previously.
  • Substituted 2- hydroxybenzaldehyde depicted as starting material is commercially available. Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible.
  • Scheme 7 represents a general scheme for the preparation of substituted- tetrahydrobenzo[f][1,4]oxazepines used in the invention.
  • R 8 is as defined previously.
  • 2-Hydroxybenzamide depicted as starting material is commercially available. Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible.
  • Scheme 8 represents a general scheme for the preparation of
  • R 8 and R 9 are as defined previously. Fluoronicotinaldehyde, chloronicotinaldehyde or
  • Scheme 9 represents a general scheme for the preparation of (R)-2-ethyl-2,3,4,5- tetrahydropyrido[2,3-f][1,4]oxazepine hydrochloride, and 2,2-dimethyl-2,3,4,5- tetrahydropyrido[2,3-f][1,4]oxazepine hydrochloride used in the invention.
  • R 8 is as defined previously.
  • 3-Hydroxypicolinaldehyde depicted as starting material is commercially available. Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible.
  • Scheme 10 represents a general scheme for the preparation of (R)-2-ethyl-2,3,4,5- tetrahydropyrido[3,2-f][1,4]oxazepine used in the invention.
  • 2-Bromo-3-(bromomethyl)pyridine depicted as starting material is commercially available. Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible.
  • Scheme 11 represents a general scheme for the preparation of 2-ethyl-2,3,4,5- tetrahydrobenzo[f][1,4]oxazepine hydrochloride, and 2,2-dimethyl-2,3,4,5- tetrahydrobenzo[f][1,4]oxazepine hydrochloride used in the invention.
  • R 7 , R 8 and R 9 are as defined previously.
  • Substituted 1-bromo-2-(bromomethyl)benzene depicted as starting material is commercially available. Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible.
  • Scheme 12 represents a general scheme for the preparation of 2,2,8-trimethyl-2,3,4,5- tetrahydropyrido[3,4-f][1,4]oxazepine hydrochloride used in the invention.
  • 4-hydroxy-6- methylnicotinic acid depicted as starting material is commercially available.
  • Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible.
  • Scheme 13 represents a general scheme for the preparation of intermediates 4, 8 and compounds according to Formula (I).
  • R 6 is C 1-3 alkyl, halo, or -OC 1-3 alkyl
  • R 7 , R 8 and R 9 are as defined previously.
  • Y is independently CH or N.
  • CH 2 CHCO 2 C 1-2 alkyl, Pd(OAc) 2 , P(o-Tol) 3 , DMF; d) 2, Rh(cod)Cl 2 , TEA; e) (i) 5, SOCl 2 , DCM; (ii) 6, K 2 CO 3 , NaI, MeCN (iii) NaOH, MeOH/H 2 O
  • Scheme 14 represents a general scheme for the preparation of intermediates 2 and 5 and compounds of Formula (I).
  • R 6 , R 7 , R 8 , R 9 and Y are as previously defined.
  • Z is CH or N.
  • the commercially available indanone 1 was either first reduced to the hydroxy indane then converted to the boronic ester or converted directly to the boronic ester by treating with bis(pinacolato)diboron in the presence of a palladium catalyst to afford 2.
  • the intermediate 3 was converted to 4 under Heck reaction conditions.
  • a chloride is used for the Heck coupling in the presence of tetrakis(triphenylphosphine) palladium rather than bromide.
  • Rhodium catalyzed Michael addition of 2 with 4 provides ester 5.
  • Intermediate 5 can be converted to the hydroxy indane by reduction with NaBH 4 if necessary and then subsequently to the chloride via treatment with SOCl 2 .
  • Conversion to the final product 7 is accomplished via treatment of the chloride with 6 and K 2 CO 3 , NaI followed by hydrolysis with NaOH.
  • Scheme 15 represents a general scheme for the preparation of intermediates 3, 6 and compounds according to Formula (II).
  • R 6 is defined previously.
  • R 10 is C 1-3 alkyl, CN.
  • Reaction of the commercially available indanone 1 with LiHMDS and benzyl bromoacetate in the presence of a suitable solvent produces desired intermediate 2.
  • Further transformation of intermediate 2 with bis(pinacolato)diboron, PdCl 2 (dppf)-CH 2 Cl 2 and KOAc in a suitable solvent yields desired intermediate 3.
  • Reaction of the commercially available ketone 4 with p- TolSO 2 CH 2 NC, KOBu-t in suitable solvent produces desired intermediate 5 which can be further converted into amine 6 via LAH reduction.
  • the triazole 7 depicted as starting material may be synthesized from readily available materials. Reaction conditions are as described above in the Scheme; however, the skilled artisan will appreciate that certain modifications in the reaction conditions and/or reagents used are possible. Treatment of triazole 7 with ethyl acrylate in the presence of palladium (II) acetate and diisopropylethyl amine in the presence of a suitable solvent produces the desired Heck cross-coupling product 8. Coupling of 3 and 8 with
  • Scheme 16 represents a general scheme for the preparation of intermediates 5 and 8.
  • R 6 is as defined previously.
  • intermediate 2 Reaction of the commercially available alcohol 1 with CDI and DMAP produces intermediate 2.
  • the intermediate 3 depicted as starting material may be synthesized from readily available materials as depicted in Scheme 16.
  • the deprotection of Boc group of intermediate 3 with HCl in 1,4-dioxane produces intermediate 4.
  • the intermediate 4 may be converted into amide product 5 by first amide formation using T3P followed by conversion of the ester to the acid.
  • Urea product 6 may be obtained by first treating 4 with CDI followed by treatment with a suitable amine and then conversion of the ester to the acid.
  • Carbamate 7 may be obtained by treatment with intermediate 2 then conversion of the ester to the acid.
  • Scheme 18 represents a general scheme for the preparation of intermediates 6 and compounds according to Formula (II).
  • R 6 is as defined previously.
  • Scheme 19 represents a general scheme for the preparation of intermediates 5 and compounds according to Formula (II).
  • R 6 is as defined previously.
  • Scheme 20 represents a general scheme for the preparation of compounds according to Formula (I).
  • aryl-bromide 3 can be transformed into aldehyde 4, which can be converted to ⁇ , ⁇ -unsaturated ester 6 under standard Wittig olefination conditions with ylide 5.
  • 1,4 addition of ketene-acetal 7 to ⁇ , ⁇ -unsaturated ester 6 can be accomplished by addtion of tetrabutylammonium benzoate in THF to afford methyl-ester 8.
  • Bromide 10 can be accessed by subjecting alcohol 9 to carbon tetrabromide and polymer supported triphenylphosphine.
  • Displacement of bromide 10 to afford cyano 11 can be accomplished by heating sodium cyanide in the proper ratio of tetrahydrofuran, water, and methanol to the appropriate temperature.
  • tetrazole 13 can be achieved by heating cyano 11 in the presence of trimethylsilylazide and tetrabutyl ammonium fluoride trihydrate in a microwave reactor, followed by alkylation with iodoethane and triethylamine. Subsequent deprotection will then afford benzylic alcohol 14. Conversion of the benzylic alcohol to the amine is accomplished via bromination and reaction with amine 15. This amine can then be hydrolized under basic microwave reactor conditions to afford 16.
  • Scheme 21 represents an alternative general scheme for the preparation of compounds according to Formula (I).
  • aryl-bromide 1 can be transformed into aldehyde 2, which can be converted to ⁇ , ⁇ -unsaturated ester 4 under standard Wittig olefination conditions with ylide 3.
  • 1,4 addition of silyl ketene acetal 5 to ⁇ , ⁇ -unsaturated ester 4 can be accomplished by addtion of tetrabutylammonium benzoate in THF to afford allyl-ester 6.
  • tetrabutylammonium benzoate in THF to afford allyl-ester 6.
  • palladium (0) catalyzed deprotection of the allyl group will afford carboxylic acid 7, which can be subsequently reduced to produce alcohol 8.
  • the compounds according to Formulas I and (II) are NRF2 regulators, and are useful in the treatment or prevention of human diseases that exhibit oxidative stress components such as respiratory and non-respiratory disorders, including COPD, asthma, fibrosis, chronic and acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, ⁇ 1 antitrypsin disease, cystic fibrosis, autoimmune diseases, diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation, Pulmonary Arterial Hypertension, atherosclerosis, hypertension, heart failure, Parkinson’s disease (PD), Alzheimer’s disease (AD), Friedreich’s Ataxia (FA), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), inflammatory bowel disease, colon cancer, neovascular (dry) AMD and neovascular (wet) AMD, eye injury, Fuchs Endothelial Corneal Dys
  • the biological activity of the compounds according to Formulas (I) and II can be determined using any suitable assay for determining the activity of a candidate compound as a NRF2 antagonist, as well as tissue and in vivo models.
  • NAD(P)H:quinone oxidoreductase 1 (NQO1) also called DT diaphorase
  • NQO1 is a homodimeric FAD-containing enzyme that catalyzes obligatory NAD(P)H-dependent two- electron reductions of quinones and protects cells against the toxic and neoplastic effects of free radicals and reactive oxygen species arising from one-electron reductions.
  • the transcription of NQO1 is finely regulated by NRF2, and thus NQO1 activity is a good marker for NRF2 activation.
  • frozen BEAS-2B cells ATCC are thawed in a water bath, counted, and re-suspended at a concentration of 250,000 cells/mL.
  • Fifty microliters of cells are plated in 384 well black clear-bottomed plates. Plates are incubated at 37°C, 5% CO 2 overnight. On day two, plates are centrifuged and 50nL of compound or controls are added to the cells. Plates are then incubated at 37°C, 5% CO 2 for 48 hours. On day four, medium is aspirated from the plate and crude cell lysates are made by adding 13uL of 1X Cell Signaling Technologies lysis buffer with 1 Complete, Mini, EDTA-free Protease Inhibitor Tablet (Roche) for each 10mL of lysis buffer . After lysis plates are incubated for 20 minutes at room temperature.
  • MTT cocktail is prepared (Prochaska et. al.1998) for measurement of NQO1 activity. Fifty microliters of MTT cocktail is added to each well, plate is centrifuged, and analyzed on an Envision plate reader (Perkin Elmer) using Absorbance 570nm label for 30 minutes. Product formation is measured kinetically and the pEC 50 of NQO1 specific activity induction is calculated by plotting the change in absorbance (Delta OD/min) versus the log of compound concentration followed by 3-parameter fitting.
  • the Keap1 protein consists of an N-terminal region (NTR), a broad complex, tramtrack, and brick a’ brac domain (BTB), an intervening region (IVR), a double glycine repeat domain (DGR or Kelch), and a C-terminal region.
  • NTR N-terminal region
  • BTB brac domain
  • IVR intervening region
  • DGR or Kelch double glycine repeat domain
  • C-terminal region The DLG and ETGE motifs of NRF2’s Neh2 domain bind to the Kelch domain of Keap1 at different affinities.
  • Keap1 Kelch fluorescence polarization (FP) assay a TAMRA- labeled 16mer peptide (AFFAQLQLDEETGEFL) containing the ETGE motif of NRF2 and the Kelch domain (321-609) of Keap1 is used.
  • the assay determines if a compound interferes with the binding between Keap1 (361-609) and the TAMRA-labeled peptide. Binding of TAMRA- labeled NRF2 peptide to Keap1 (321-609) results in a high FP signal. If a compound interferes with the binding between the peptide and the protein, it will cause the assay signal to decrease. Thus, assay signal is inversely proportional to binding inhibition.
  • FP assay :
  • 100nl of 100X compound dose response curves (serial 3-fold dilutions) in DMSO are stamped using an Echo liquid handling system (Labcyte) into 384-well low volume black assay plates (Greiner, #784076), with DMSO in columns 6 and 18.
  • the top concentration of compound is located in columns 1 and 13.
  • Keap1 (321-609) is diluted to 40nM (2X) in 1X assay buffer (50 mM Tris, pH 8.0, 100mM NaCl, 5mM MgCl 2 , 1mM DTT, 2mM CHAPS, and 0.005% BSA) and 5ul is added using a Multidrop Combi (Thermo Electron Corporation) equipped with a metal tip dispenser to all wells of the compound plate, except column 18. Column 18 receives only 5ul of assay buffer. Immediately, 5 uL of 16 nM (2X) of Tamra labeled peptide
  • Abase XE uses a four parameter equation.
  • NRF2-Keap1 TR-FRET time-resolved fluorescence resonance energy transfer
  • full length NRF2 protein and full length Keap1 protein Keap1 exists a dimer
  • the assay detects the ability of compound to displace the binding of FlagHis-tagged Keap1 with biotinylated, Avi-tagged NRF2 protein.
  • Biotin-NRF2 binds to streptavidin-europium (a component of the detection mix) and Keap1- FlagHis is recognized by anti-Flag APC
  • Keap1 antibody also a component of the detection mix. If binding occurs between the two proteins, there will be an energy transfer from the Eu+3 (donor) at 615 nm to the APC (acceptor) at 665 nm. A potential Keap1 inhibitor will cause a reduction in the TR-FRET signal by interfering with the binding of Keap1 to NRF2.
  • Keap1-FlagHis protein is added to all wells of the compound plate, with the exception of the wells in column 18.
  • Wells in column 18 receive 5 ul of assay buffer instead. Plates are centrifuged at 500 rpm for 1 minute, covered with a plate lid, and incubated at 37°C for 2.25 hours. Plates are then removed from the incubator and allowed to cool to RT for 15 minutes. Five microliters of 50 nM biotin-NRF2 protein is then added to all wells of the plates and the plates are spun at 500 rpm for 1 minute, followed by incubating at 4°C for 1.25 hours.
  • the plates are then allowed to warm to RT for 15 minutes, followed by the addition of 10 ul of detection mix (1 nM Streptavidin Eu+ W1024 and 5 ug/ml mouse anti-DYKDDDDK IgG conjugated to SureLight APC antibody; both from Columbia Biosciences) to all wells. Plates are spun at 500 rpm for 1 minute, incubated for 1 hour at RT, and read on an Envision plate reader using a 320 nm excitation filter and 615 nm and 665 nm emission filters.
  • Abase XE uses a four parameter equation.
  • NRF2-Keap1 TR-FRET time-resolved fluorescence resonance energy transfer low protein assay
  • full length NRF2 protein and full length Keap1 protein (Keap1 exists a dimer) are used.
  • the assay detects a compound’s ability to displace the binding of Keap1 FlagHis with biotinylated Avi-NRF2 protein.
  • Biotin-NRF2 binds to streptavidin-europium (a component of the detection mix) and Keap1 FlagHis is recognized by anti-Flag APC (allophycocyanin) antibody (also a component of the detection mix).
  • the BSA, DTT, and CHAPS are added to the assay buffer on the day of assay.
  • 5 ul of 1.25 nM Keap1 FlagHis protein is added to all wells of the compound plate, with the exception of the wells in column 18.
  • Wells in column 18 receive 5ul of assay buffer instead. Plates are centrifuged at 500 rpm for 1 minute, covered with a plate lid, and incubated at 37°C for 2.25 hours. Plates are then removed from the incubator and allowed to cool to RT for 15 minutes.
  • Abase XE uses a four parameter equation.
  • the compounds of the invention are NRF2 regulators, and are useful in the treatment or prevention of respiratory disorders, including COPD, asthma, fibrosis, lung infection, diabetic nephropathy/chronic kidney disease, autoimmune diseases (e.g., multiple sclerosis and inflammatory bowel disease), eye diseases (e.g., AMD, Fuchs, and uveitis), cardiovascular diseases, Non-alcoholic steatohepatitis (NASH), Parkinson’s, Alzheimer’s, psoriasis, acute kidney injury, topical effects of radiation, and kidney transplant.
  • respiratory disorders including COPD, asthma, fibrosis, lung infection, diabetic nephropathy/chronic kidney disease, autoimmune diseases (e.g., multiple sclerosis and inflammatory bowel disease), eye diseases (e.g., AMD, Fuchs, and uveitis), cardiovascular diseases, Non-alcoholic steatohepatitis (NASH), Parkinson’s, Alzheimer’s, psoriasis, acute kidney injury, topical effects of
  • the invention is directed to methods of treating such conditions.
  • the methods of treatment of the invention comprise administering a safe and effective amount of a compound according to Formula I or a pharmaceutically-acceptable salt thereof to a patient in need thereof.
  • treat in reference to a condition means: (1) to ameliorate or prevent the condition or one or more of the biological manifestations of the condition, (2) to interfere with (a) one or more points in the biological cascade that leads to or is responsible for the condition or (b) one or more of the biological manifestations of the condition, (3) to alleviate one or more of the symptoms or effects associated with the condition, or (4) to slow the progression of the condition or one or more of the biological manifestations of the condition.
  • prevention is not an absolute term. In medicine, “prevention” is understood to refer to the prophylactic administration of a drug to substantially diminish the likelihood or severity of a condition or biological manifestation thereof, or to delay the onset of such condition or biological manifestation thereof.
  • safe and effective amount in reference to a compound of the invention or other pharmaceutically-active agent means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects (at a reasonable benefit/risk ratio) within the scope of sound medical judgment.
  • a safe and effective amount of a compound will vary with the particular compound chosen (e.g. consider the potency, efficacy, and half-life of the compound); the route of administration chosen; the condition being treated; the severity of the condition being treated; the age, size, weight, and physical condition of the patient being treated; the medical history of the patient to be treated; the duration of the treatment; the nature of concurrent therapy; the desired therapeutic effect; and like factors, but can nevertheless be routinely determined by the skilled artisan.
  • patient refers to a human or other animal.
  • the compounds of the invention may be administered by any suitable route of administration, including both systemic administration and topical administration.
  • Systemic administration includes oral administration, parenteral administration, transdermal
  • Parenteral administration refers to routes of administration other than enteral, transdermal, or by inhalation, and is typically by injection or infusion.
  • Parenteral administration includes intravenous, intramuscular, and subcutaneous injection or infusion.
  • Inhalation refers to administration into the patient's lungs whether inhaled through the mouth or through the nasal passages.
  • Topical administration includes application to the skin as well as intraocular, otic, intravaginal, and intranasal administration.
  • the compounds of the invention may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. For example, doses may be administered one, two, three, or four times per day. Doses may be administered until the desired therapeutic effect is achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing regimens for a compound of the invention depend on the pharmacokinetic properties of that compound, such as absorption, distribution, and half-life, which can be determined by the skilled artisan.
  • suitable dosing regimens including the duration such regimens are administered, for a compound of the invention depend on the condition being treated, the severity of the condition being treated, the age and physical condition of the patient being treated, the medical history of the patient to be treated, the nature of concurrent therapy, the desired therapeutic effect, and like factors within the knowledge and expertise of the skilled artisan. It will be further understood by such skilled artisans that suitable dosing regimens may require adjustment given an individual patient's response to the dosing regimen or over time as individual patient needs change.
  • Typical daily dosages may vary depending upon the particular route of administration chosen. Typical dosages for oral administration range from 1 mg to 1000 mg per person per day. Preferred dosages are 1– 500 mg once daily, more preferred is 1– 100 mg per person per day. IV dosages range form 0.1-000mg/day, preferred is 0.1-500mg/day, and more preferred is 0.1-100mg/day. Inhaled daily dosages range from 10ug-10mg/day, with preferred 10ug-2mg/day, and more preferred 50uug-500ug/day.
  • a prodrug of a compound of the invention is a functional derivative of the compound which, upon administration to a patient, eventually liberates the compound of the invention in vivo.
  • Administration of a compound of the invention as a prodrug may enable the skilled artisan to do one or more of the following: (a) modify the onset of the compound in vivo; (b) modify the duration of action of the compound in vivo; (c) modify the transportation or distribution of the compound in vivo; (d) modify the solubility of the compound in vivo; and (e) overcome a side effect or other difficulty encountered with the compound.
  • Typical functional derivatives used to prepare prodrugs include modifications of the compound that are chemically or enzymatically cleaved in vivo. Such modifications, which include the preparation of phosphates, amides, ethers, esters, thioesters, carbonates, and carbamates, are well known to those skilled in the art.
  • the compounds of the invention will normally, but not necessarily, be formulated into pharmaceutical compositions prior to administration to a patient. Accordingly, in another aspect the invention is directed to pharmaceutical compositions comprising a compound of the invention and one or more pharmaceutically-acceptable excipient.
  • compositions of the invention may be prepared and packaged in bulk form wherein a safe and effective amount of a compound of the invention can be extracted and then given to the patient such as with powders or syrups.
  • the pharmaceutical compositions of the invention may be prepared and packaged in unit dosage form wherein each physically discrete unit contains a safe and effective amount of a compound of the invention.
  • the pharmaceutical compositions of the invention typically contain from 1 mg to 1000 mg.
  • compositions of the invention typically contain one compound of the invention. However, in certain embodiments, the pharmaceutical compositions of the invention contain more than one compound of the invention. For example, in certain embodiments the pharmaceutical compositions of the invention contain two compounds of the invention. In addition, the pharmaceutical compositions of the invention may optionally further comprise one or more additional pharmaceutically active compounds.
  • pharmaceutically-acceptable excipient means a pharmaceutically acceptable material, composition or vehicle involved in giving form or consistency to the pharmaceutical composition.
  • Each excipient must be compatible with the other ingredients of the pharmaceutical composition when commingled such that interactions which would substantially reduce the efficacy of the compound of the invention when administered to a patient and interactions which would result in pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
  • each excipient must of course be of sufficiently high purity to render it pharmaceutically-acceptable.
  • dosage forms include those adapted for (1) oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets; (2) parenteral administration such as sterile solutions, suspensions, and powders for reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal administration such as suppositories; (5) inhalation such as dry powders, aerosols, suspensions, and solutions; and (6) topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams, and gels.
  • oral administration such as tablets, capsules, caplets, pills, troches, powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets
  • parenteral administration such as sterile solutions, suspensions, and powders for reconstitution
  • transdermal administration such as transdermal patches
  • rectal administration such as
  • Suitable pharmaceutically-acceptable excipients will vary depending upon the particular dosage form chosen.
  • suitable pharmaceutically-acceptable excipients may be chosen for a particular function that they may serve in the composition.
  • certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of uniform dosage forms.
  • Certain pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the production of stable dosage forms.
  • pharmaceutically-acceptable excipients may be chosen for their ability to facilitate the carrying or transporting of the compound or compounds of the invention once administered to the patient from one organ, or portion of the body, to another organ, or portion of the body. Certain pharmaceutically-acceptable excipients may be chosen for their ability to enhance patient compliance.
  • Suitable pharmaceutically-acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants, preservatives, stabilizers, surfactants, and buffering agents.
  • excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers, sweeteners, flavoring agents, flavor masking agents, coloring agents, anticaking agents, hemectants, chel
  • compositions of the invention are prepared using techniques and methods known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
  • the invention is directed to a solid oral dosage form such as a tablet or capsule comprising a safe and effective amount of a compound of the invention and a diluent or filler.
  • Suitable diluents and fillers include lactose, sucrose, dextrose, mannitol, sorbitol, starch (e.g. corn starch, potato starch, and pre-gelatinized starch), cellulose and its derivatives (e.g. microcrystalline cellulose), calcium sulfate, and dibasic calcium phosphate.
  • the oral solid dosage form may further comprise a binder. Suitable binders include starch (e.g.
  • the oral solid dosage form may further comprise a disintegrant. Suitable
  • disintegrants include crospovidone, sodium starch glycolate, croscarmelose, alginic acid, and sodium carboxymethyl cellulose.
  • the oral solid dosage form may further comprise a lubricant. Suitable lubricants include stearic acid, magnesium stearate, calcium stearate, and talc.
  • the invention is directed to a dosage form adapted for administration to a patient parenterally including subcutaneous, intramuscular, intravenous or intradermal.
  • Pharmaceutical formulations adapted for parenteral administration include aqueous and non- aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • sterile liquid carrier for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
  • the invention is directed to a dosage form adapted for administration to a patient by inhalation.
  • the compound of the invention may be inhaled into the lungs as a dry powder, an aerosol, a suspension, or a solution.
  • Dry powder compositions for delivery to the lung by inhalation typically comprise a compound of the invention as a finely divided powder together with one or more
  • pharmaceutically acceptable excipients as finely divided powders.
  • Pharmaceutically acceptable excipients particularly suited for use in dry powders are known to those skilled in the art and include lactose, starch, mannitol, and mono-, di-, and polysaccharides.
  • compositions for use in accordance with the present invention are administered via inhalation devices.
  • such devices can encompass capsules and cartridges of for example gelatin, or blisters of, for example, laminated aluminum foil.
  • each capsule, cartridge or blister may contain doses of composition according to the teachings presented herein.
  • inhalation devices can include those intended for unit dose or multi-dose delivery of composition, including all of the devices set forth herein.
  • the formulation can be pre-metered (e.g., as in Diskus ⁇ , see GB2242134, U.S.
  • Patent Nos.6,032,666, 5,860,419, 5,873,360, 5,590,645, 6,378,519 and 6,536,427 or Diskhaler see GB 2178965, 2129691 and 2169265, US Pat. Nos.4,778,054, 4,811,731, 5,035,237) or metered in use (e.g. as in Turbuhaler, see EP 69715, or in the devices described in U.S. Patent No 6,321,747).
  • An example of a unit-dose device is Rotahaler (see GB 2064336).
  • the Diskus ⁇ inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing the compound optionally with other excipients and additive taught herein.
  • the peelable seal is an engineered seal, and in one embodiment the engineered seal is a hermetic seal.
  • the strip is sufficiently flexible to be wound into a roll.
  • the lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the leading end portions is constructed to be attached to a winding means.
  • the engineered seal between the base and lid sheets extends over their whole width.
  • the lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the base sheet.
  • a dry powder composition may also be presented in an inhalation device which permits separate containment of two different components of the composition.
  • these components are administrable simultaneously but are stored separately, e.g. in separate pharmaceutical compositions, for example as described in WO 03/061743 A1 WO 2007/012871 A1 and/or WO2007/068896.
  • an inhalation device permitting separate containment of components is an inhaler device having two peelable blister strips, each strip containing pre-metered doses in blister pockets arranged along its length, e.g., multiple containers within each blister strip.
  • Said device has an internal indexing mechanism which, each time the device is actuated, peels opens a pocket of each strip and positions the blisters so that each newly exposed dose of each strip is adjacent to the manifold which communicates with the mouthpiece of the device. When the patient inhales at the mouthpiece, each dose is simultaneously drawn out of its associated pocket into the manifold and entrained via the mouthpiece into the patient's respiratory tract.
  • a further device that permits separate containment of different components is DUOHALER TM of Innovata.
  • various structures of inhalation devices provide for the sequential or separate delivery of the
  • composition(s) from the device, in addition to simultaneous delivery.
  • Aerosols may be formed by suspending or dissolving a compound of the invention in a liquefied propellant.
  • Suitable propellants include halocarbons, hydrocarbons, and other liquefied gases.
  • Representative propellants include: trichlorofluoromethane (propellant 11),
  • dichlorofluoromethane (propellant 12), dichlorotetrafluoroethane (propellant 114),
  • HFA-134a 1,1-difluoroethane
  • HFA-152a 1,1-difluoroethane
  • HFA-32 difluoromethane
  • pentafluoroethane HFA-12
  • heptafluoropropane HFA- 227a
  • perfluoropropane
  • Aerosols comprising a compound of the invention will typically be administered to a patient via a metered dose inhaler (MDI). Such devices are known to those skilled in the art.
  • MDI metered dose inhaler
  • the aerosol may contain additional pharmaceutically acceptable excipients typically used with multiple dose inhalers such as surfactants, lubricants, cosolvents and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
  • additional pharmaceutically acceptable excipients typically used with multiple dose inhalers such as surfactants, lubricants, cosolvents and other excipients to improve the physical stability of the formulation, to improve valve performance, to improve solubility, or to improve taste.
  • Suspensions and solutions comprising a compound of the invention may also be administered to a patient via a nebulizer.
  • the solvent or suspension agent utilized for nebulization may be any pharmaceutically acceptable liquid such as water, aqueous saline, alcohols or glycols, e.g., ethanol, isopropyl alcohol, glycerol, propylene glycol, polyethylene glycol, etc. or mixtures thereof.
  • Saline solutions utilize salts which display little or no
  • organic salts such as alkali metal or ammonium halogen salts, e.g., sodium chloride, potassium chloride or organic salts, such as potassium, sodium and ammonium salts or organic acids, e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc. may be used for this purpose.
  • organic acids e.g., ascorbic acid, citric acid, acetic acid, tartaric acid, etc.
  • Other pharmaceutically acceptable excipients may be added to the suspension or solution.
  • the compound of the invention may be stabilized by the addition of an inorganic acid, e.g., hydrochloric acid, nitric acid, sulfuric acid and/or phosphoric acid; an organic acid, e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc., a complexing agent such as EDTA or citric acid and salts thereof; or an antioxidant such as antioxidant such as vitamin E or ascorbic acid.
  • an inorganic acid e.g., hydrochloric acid, nitric acid, sulfuric acid and/or phosphoric acid
  • an organic acid e.g., ascorbic acid, citric acid, acetic acid, and tartaric acid, etc.
  • a complexing agent such as EDTA or citric acid and salts thereof
  • an antioxidant such as antioxidant such as vitamin E or ascorbic acid.
  • Preservatives may be added such as benzalkonium chloride or benzoic acid and salts thereof.
  • Surfactant
  • the compounds of Formulas (I) and (II) and pharmaceutically acceptable salts thereof may be used in combination with one or more other agents which may be useful in the prevention or treatment of allergic disease, inflammatory disease, autoimmune disease, for example; antigen immunotherapy, anti-histamines, corticosteroids, (eg fluticasone propionate, fluticasone furoate, beclomethasone dipropionate, budesonide, ciclesonide, mometasone furoate, triamcinolone, flunisolide), NSAIDs, leukotriene modulators (e.g.
  • iNOS inhibitors e.g., montelukast, zafirlukast, pranlukast
  • iNOS inhibitors tryptase inhibitors, IKK2 inhibitors, p38 inhibitors, Syk inhibitors
  • protease inhibitors such as elastase inhibitors, integrin antagonists (e.g., beta-2 integrin antagonists), adenosine A2a agonists, mediator release inhibitors such as sodium chromoglycate, 5-lipoxygenase inhibitors (zyflo), DP1 antagonists, DP2 antagonists, PI3K delta inhibitors, ITK inhibitors, LP (lysophosphatidic) inhibitors or FLAP (5-lipoxygenase activating protein) inhibitors (e.g.
  • bronchodilators e.g., muscarinic antagonists, beta-2 agonists
  • methotrexate and similar agents
  • monoclonal antibody therapy such as anti-IgE, anti-TNF, anti-IL-5, anti-IL-6, anti-IL-12, anti-IL-1 and similar agents
  • cytokine receptor therapies e.g.
  • antigen non-specific immunotherapies e.g. interferon or other cytokines/chemokines, chemokine receptor modulators such as CCR3, CCR4 or CXCR2 antagonists, other cytokine/chemokine agonists or antagonists, TLR agonists and similar agents.
  • the compounds may also be used in combination with agents for aiding transplantation including Cyclosporines, Tacrolimus, Mycophenolate mofetil, Prednisone, Azathioprine , Sirolimus, Daclizumab, Basiliximab, or OKT3.
  • agents for aiding transplantation including Cyclosporines, Tacrolimus, Mycophenolate mofetil, Prednisone, Azathioprine , Sirolimus, Daclizumab, Basiliximab, or OKT3.
  • diabetes may also be used in combination with agents for Diabetes: metformin (biguanides), meglitinides, sulfonylureas, DPP-4 inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Amylin mimetics, Incretin mimetics, and insulin.
  • metformin biguanides
  • meglitinides meglitinides
  • sulfonylureas DPP-4 inhibitors
  • Thiazolidinediones Thiazolidinediones
  • Alpha-glucosidase inhibitors Amylin mimetics
  • Incretin mimetics and insulin.
  • the compounds may be used in combination with antihypertensives such as diuretics, ACE inhibitors, ARBS, calcium channel blockers, and beta blockers.
  • antihypertensives such as diuretics, ACE inhibitors, ARBS, calcium channel blockers, and beta blockers.
  • One embodiment of the invention encompasses combinations comprising one or two other therapeutic agents.
  • the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates to optimize the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient.
  • the therapeutic ingredients may be used in optically pure form.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
  • the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.
  • the individual compounds will be administered simultaneously in a combined pharmaceutical formulation.
  • Appropriate doses of known therapeutic agents will readily be appreciated by those skilled in the art.
  • the invention thus provides, in a further aspect, a pharmaceutical composition comprising a combination of a compound of the invention together with another therapeutically active agent.
  • Preparative HPLC was performed using a Gilson or Waters Preparative System with variable wavelength UV detection or an Agilent Mass Directed AutoPrep (MDAP) system or Shimadzu PREP LC 20AP with both mass and variable wavelength UV detection.
  • MDAP Agilent Mass Directed AutoPrep
  • a variety of reverse phase columns e.g., Luna C18(2), SunFire C18, XBridge C18, Atlantics T3, Kromasil C18, Xbridge Phenyl-Hexyl columns were used in the purification with the choice of column support dependent upon the conditions used in the purification.
  • the compounds were eluted using a gradient of CH 3 CN or methanol and water.
  • Neutral conditions used an CH 3 CN and water gradient with no additional modifier
  • acidic conditions used an acid modifier, usually 0.1% TFA or 0.1% formic acid
  • basic conditions used a basic modifier, usually 0.1% NH 4 OH (added to the water) or 10 mM ammonium bicarbonate (added to the water), or 0.05 %
  • Analytical HPLC was run using an Agilent system or Waters Alliance HPLC with 2996 PDA detector, Waters Acquity UPLC-MS or Agilent Infinity 1290 with PDA or conducted on a Sunfire C18 column, alternative on XSELECT CSH C18 column using reverse phase chromatography with a CH 3 CN and water gradient with 0.1% formic acid modifier (added to each solvent) and basic conditions used a basic modifier, usually 5mM ammonium bicarbonate or 10 mM ammonium bicarbonate in water adjusted pH to 10 with ammonia solution.
  • a basic modifier usually 5mM ammonium bicarbonate or 10 mM ammonium bicarbonate in water adjusted pH to 10 with ammonia solution.
  • the compound was analyzed by LCMS using a Shimadzu LC system with UV 214 nm wavelength detection and H 2 O- CH 3 CN gradient elution (4-95% over 1.9min.) acidified to 0.02% TFA.
  • the reversed-phase column was a 2.1x20 mm Thermo Hypersil Gold C18 (1.9u particles) at 50 ⁇ C.
  • the single quadrupole MS detector was either a Sciex 150EX or a Waters ZQ operated in positive-ion.
  • LC-MS was determined using either a PE Sciex Single Quadrupole 150EX LC-MS, or Waters ZQ Single Quadrupole, Waters 3100 Single Quadrupole, Agilent 6130 SQD or Agilent 6120 Single Quadrupole LC-MS instruments.
  • the compound is analyzed using a reverse phase column, e.g., Thermo Hypersil Gold C18 and/or Luna C18 eluted using a gradient of CH 3 CN and water with a low percentage of an acid modifier such as 0.02% or 0.1%TFA.
  • Preparative Chiral SFC was performed using a Thar/Waters Preparative SFC System with single wavelength UV detection system.
  • a variety of chiral SFC columns e.g. Chiralpak IA, IC, AY, AD, IF, OJ were used in the purification.
  • the compounds are eluted using supercritical fluid CO 2 and co-solvents, such as MeOH, EtOH, IPA, and combination of these solvent in different ratio based on the compound.
  • Modifiers (0.1% to 0.4% of TFA, NH 4 OH, DEA, TEA) can be used as needed.
  • a variety of chiral SFC columns e.g. Chiralpak IA, IB, IC, ID, IF, AY, AD, OD, C2, AS, OJ, CCL4 were used in the purification.
  • the compounds are eluted using supercritical fluid CO 2 and co-solvents, such as MeOH, EtOH, IPA, and combination of these solvent in different ratio based on the compound selectivity. Modifiers (0.1% to 0.4% of TFA, NH 4 OH, DEA, TEA) would be used as needed.
  • Celite ® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
  • Isolute ® is a functionalized silica gel based sorbent, and is a registered trademark of Biotage AB Corp., Sweden.
  • Heating of reaction mixtures with microwave irradiation was carried out on a Biotage Initiator ® microwave reactor, typically employing the high absorbance setting.
  • Cartridges or columns containing polymer based functional groups can be used as part of compound workup.
  • the "amine” columns or cartridges are used to neutralize or basify acidic reaction mixtures or products. These include NH 2 Aminopropyl SPE-ed SPE Cartridges available from Applied Separations and diethylamino SPE cartridges available from United Chemical Technologies, Inc. Table of Abbreviations
  • the filtrate was concentrated under reduced pressure to afford a crude residue.
  • the crude residue was purified by column chromatography using 20% ethyl acetate in n-hexane as eluent. The eluted fractions were concentrated under reduced pressure to afford the title compound (12 g, 82 % yield).
  • This intermediate was dissolved in DCM (6 mL) after which (4-ethylcyclohexyl)methanamine (85 mg, 0.600 mmol), TEA (0.084 mL, 0.600 mmol) and then T3P (50% wt in EtOAc) (0.179 mL, 0.600 mmol) were added.
  • the resulting reaction mixture was stirred at ambient temperature for 43 h after which TEA (0.042 mL, 0.300 mmol) and T3P (50% wt in EtOAc) (0.089 mL, 0.300 mmol) was added and stirred at ambient temperature for another 94 h.
  • reaction mixture was purified via silica gel chromatography to afford the desired product ethyl 3-(2-(2- ((cyclohexylmethyl)amino)-2-oxoethyl)-3-oxo-2,3-dihydro-1H-inden-5-yl)-5-(1-ethyl-1H-1,2,3- triazol-4-yl)pentanoate (119.8 mg, 0.236 mmol, 59.3 % yield).
  • LC-MS m/z 509.3 (M+H) + , 0.99 min (ret. time).
  • the resulting reaction mixture was heated with microwave at 120 °C for 1 h; heated again with microwave at 120 °C for 2 h; heated again with microwave at 130 °C for 1 h.
  • the reaction mixture was concentrated under reduced pressure, dissolved in methanol (3 mL) and then NaOH (3.0 N) (0.624 mL, 1.872 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 °C for 20 min.
  • This intermediate was dissolved in DCM (6 mL) after which (4-propylcyclohexyl)methanamine (93 mg, 0.600 mmol), TEA (0.084 mL, 0.600 mmol) and then T3P (50% wt in EtOAc) (0.357 mL, 0.600 mmol) was added. The resulting reaction mixture was stirred at ambient temperature for 2 h before adding more T3P (50% wt in EtOAc) (0.179 mL, 0.300 mmol) and TEA (0.042 mL, 0.300 mmol). The resulting reaction mixture was stirred at ambient temperature for another 68 h.
  • reaction mixture was purified via silica gel chromatography to afford the desired product ethyl 3-(1,4-dimethyl-1H- benzo[d][1,2,3]triazol-5-yl)-3-(3-oxo-2-(2-oxo-2-(((4-propylcyclohexyl)methyl)amino)ethyl)-2,3- dihydro-1H-inden-5-yl)propanoate (146.2 mg, 0.255 mmol, 85 % yield).
  • LC-MS m/z 573.4 (M+H) + , 1.25 min (ret. time).
  • Methyl 2-(6-bromo-1-oxo-2,3-dihydro-1H-inden-2-yl)acetate To a solution of 6-bromo-2,3-dihydro-1H-inden-1-one (15 g, 71.1 mmol) in THF (300 mL), LiHMDS (85 mL, 85 mmol) was added dropwise at -78 °C. Then the reaction mixture was allowed to warm up to 0 °C and was cooled to -78 °C again. Methyl 2-bromoacetate (7.38 mL, 78 mmol) was added dropwise at -78 °C. The reaction mixture was warmed to ambient temperature.
  • the resulting reaction mixture was stirred at ambient temperature for 70 min before adding more T3P (50% wt in EtOAc) (0.034 mL, 0.113 mmol) and TEA (0.016 mL, 0.113 mmol). The resulting reaction mixture was stirred at ambient temperature for another 3 h. To the reaction mixture was added more T3P (50% wt in EtOAc) (0.034 mL, 0.113 mmol) and TEA (0.032 mL, 0.227 mmol). The resulting reaction mixture was stirred at ambient temperature for 50 min more before adding more 2- cyclohexylacetic acid (17.74 mg, 0.125 mmol). The resulting reaction mixture was stirred at ambient temperature for another 18 h.
  • the reaction mixture was concentrated under reduced pressure, dissolved in methanol (2.000 mL) then was added NaOH (3 N) (0.378 mL, 1.134 mmol). The resulting reaction mixture was heated with microwave at 80 °C for 20 min. To the reaction mixture was added more NaOH (3 N) (0.378 mL, 1.134 mmol). The resulting reaction mixture was heated with microwave at 80 oC for another 20 min. To the reaction mixture was added more NaOH (3 N) (0.113 mL, 0.340 mmol). The resulting reaction mixture was heated with microwave at 80 oC for 20 min, heated again with microwave at 80 oC for 20 min.
  • reaction mixture was then heated with microwave at 80 oC for 30 min.
  • T3P 50% wt in EtOAc
  • TEA 0.032 mL, 0.227 mmol
  • the reaction mixture was stirred at ambient temperature for another 71 h.
  • the reaction mixture was then heated with microwave at 80 oC for 30 min.
  • the reaction mixture was concentrated under reduced pressure, dissolved in methanol (2.000 mL) then was added NaOH (3 N) (0.756 mL, 2.268 mmol).
  • the resulting reaction mixture was heated with microwave at 80 °C for 20 min.
  • To the reaction mixture was added more NaOH (3 N) (0.378 mL, 1.134 mmol).
  • reaction mixture was then heated with microwave at 80 oC for 30 min.
  • T3P 50% wt in EtOAc
  • TEA 0.032 mL, 0.227 mmol
  • the reaction mixture was stirred at ambient temperature for another 71 h.
  • the reaction mixture was then heated with microwave at 80 oC for 30 min.
  • the reaction mixture was concentrated under reduced pressure, dissolved in methanol (2.000 mL) then was added NaOH (3 N) (0.756 mL, 2.268 mmol).
  • the resulting reaction mixture was heated with microwave at 80 °C for 20 min.
  • To the reaction mixture was added more NaOH (3 N) (0.378 mL, 1.134 mmol).
  • reaction mixture was then heated with microwave at 80 oC for 30 min (33-8).
  • T3P 50% wt in EtOAc
  • TEA 0.032 mL, 0.227 mmol
  • the resulting reaction mixture was stirred at ambient temperature for 71 h.
  • the reaction mixture was concentrated under reduced pressure before being dissolved in methanol (2.000 mL) then added NaOH (3 N) (0.756 mL, 2.268 mmol).
  • the resulting reaction mixture was heated with microwave at 80 oC for 20 min before adding more NaOH (3 N) (0.378 mL, 1.134 mmol) then heated with microwave at 80 oC for 20 min.
  • the resulting reaction mixture was stirred at ambient temperature for 100 min then heated with microwave at 80 oC for 30 min.
  • To the reaction mixture was added more N-methylbutan-1-amine (0.027 mL, 0.227 mmol) then heated with microwave at 80 oC for 30 min.
  • the reaction mixture was concentrated under reduced pressure, dissolved in 1,4-dioxane (0.5 mL) then added more N-methylbutan-1-amine (0.5 mL, 4.22 mmol).
  • the resulting reaction mixture was heated with microwave at 80 oC for 30 min; heated again with microwave at 100 oC for 30 min; heated again with microwave at 120 oC for 60 min; heated again with microwave at 130 oC for 60 min.
  • the reaction mixture was concentrated under reduced pressure and dissolved in methanol (2.000 mL) after which NaOH (3 N) (0.227 mL, 0.680 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 oC for 20 min before adding more NaOH (3 N) (0.227 mL, 0.680 mmol) then heated with microwave at 80 oC for 20 min.
  • the resulting reaction mixture was heated at 90 °C for 100 min.
  • the reaction mixture was concentrated under reduced pressure and dissolved in methanol (2.000 mL) after which NaOH (3 N) (0.306 mL, 0.919 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 oC for 20 min.
  • the resulting reaction mixture was heated at 90 °C for 100 min.
  • the reaction mixture was concentrated under reduced pressure and dissolved in methanol (2.000 mL) after which NaOH (3 N) (0.309 mL, 0.926 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 oC for 20 min.
  • the resulting reaction mixture was heated at 90 °C for 100 min.
  • the reaction mixture was concentrated under reduced pressure and dissolved in methanol (2.000 mL) after which NaOH (3 N) (0.358 mL, 1.075 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 oC for 20 min.
  • reaction mixture was acidified with HCl (3 N) to pH 3 ⁇ 4 then concentrated under reduced pressure and purified with reverse phase HPLC to afford the desired product 3-(1-(tert- butoxycarbonyl)-1,2,3,3a,4,8b-hexahydroindeno[1,2-b]pyrrol-7-yl)-5-(1-ethyl-1H-1,2,3-triazol-4- yl)pentanoic acid (32.4 mg, 0.071 mmol, 53.0 % yield).
  • LC-MS m/z 455.2 (M+H) + , 0.94 min (ret. time).
  • the resulting reaction mixture was heated at 90 °C for 66 h.
  • the reaction mixture was concentrated under reduced pressure and dissolved in methanol (2.000 mL) after which NaOH (3 N) (0.306 mL, 0.919 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 oC for 20 min.
  • the reaction mixture was degassed with argon for 10 min and then stirred at 100 °C for 2 h.
  • the reaction mixture was cooled to ambient temperature, diluted with water and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with a brine solution (20 mL) and dried over Na 2 SO 4 , filtered and evaporated under vacuum.
  • the crude residue was purified by flash column chromotography, using EtOAc : Hexane (5:5) as eluent to afford the title compound (200 mg, 29.3 % yield).
  • the reaction mixture was stirred at 90 °C for 4 h.
  • the reaction mixture was passed through celite and washed with ethyl acetate.
  • the reaction was diluted with water and extracted with EtOAc.
  • the organic layer was dried over Na 2 SO 4 and filtered.
  • the filtrate was concentrated under reduced pressure and purified by column chromatograpy using (5:95) EtOAc:Hexane as eluent. The eluted fractions were evaporated to afford the title compound (215 mg, 87 % yield).
  • reaction mixture was filtered.
  • the filter cake was washed with MeCN (2 mL).
  • the combined filtrate was evaporated under vacuum, dissolved in methanol (3 mL).
  • NaOH (3 N) (0.533 mL, 1.600 mmol) was.
  • the resulting reaction mixture was heated with microwave at 80 o C for 20 min.
  • reaction mixture was filtered.
  • the filter cake was washed with MeCN (2 mL).
  • the combined filtrate was evaporated under vacuum before being diluted with methanol (2.000 mL) then NaOH (2 N) (0.552 mL, 0.230 mmol) was added.
  • the resulting reaction mixture was heated with microwave at 80 o C for 15 min.
  • the resulting solution was stirred at ambient temperature for 20 min and added sodium iodide (18.19 mg, 0.121 mmol) and methyl 3-(3-chloro-2,3-dihydro-1H-inden-5-yl)-3-(1,4-dimethyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate (100 mg, 0.243 mmol).
  • sodium iodide 18.19 mg, 0.121 mmol
  • methyl 3-(3-chloro-2,3-dihydro-1H-inden-5-yl)-3-(1,4-dimethyl-1H- benzo[d][1,2,3]triazol-5-yl)-2,2-dimethylpropanoate 100 mg, 0.243 mmol.
  • the resulting solution was heated with 50 °C for 16 h before being filtered.
  • the combined filtrate was evaporated under vacuum.
  • reaction mixture was acidified with HCl (1 N) to pH ⁇ 5, evaporated under vacuum, and purified by reverse phase HPLC to afford product 3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-((R)-2-ethyl-2,3- dihydrobenzo[f][1,4]oxazepin-4(5H)-yl)-2,3-dihydro-1H-inden-5-yl)-2,2-dimethylpropanoic acid (34 mg, 0.063 mmol, 17.23 % yield).
  • LC-MS m/z 539.5 (M+H) + , 0.85 min (ret. time).
  • reaction mixture was filtered.
  • the filter cake was washed with MeCN (2 mL).
  • the combined filtrate was evaporated under vacuum then was redissolved in methanol (3 mL) followed by addition of NaOH (3 N) (0.533 mL, 1.600 mmol).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (I), et formule (II), dans laquelle B représente benzotriazolyle, phényle, triazolopyridinyle, ou -(CH2)2-triazolyle dont chacun peut être non substitué ou substitué par 1, 2, ou 3 substituants choisis indépendamment parmi l'alkyle -C1-3, l'alkyle -O-C1-3, CN, - (CH2)2-0-(CH2)2-OR4 et l'halo; et D est -C(0)OH, -C(0)NHS02CH3, -S02NHC(0)CH3, 5-(trifluorométhyl)-4H-1,2,4-triazol-2-yl, ou tétrazolyl; et leur utilisation en tant que régulateurs de NRF2.
PCT/IB2016/057387 2016-12-06 2016-12-06 Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2 WO2018104766A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201680083119.7A CN108779108A (zh) 2016-12-06 2016-12-06 3-(2,3-二氢-1h-茚-5-基)丙酸衍生物和它们作为nrf2调节剂的用途
KR1020187017624A KR20190088404A (ko) 2016-12-06 2016-12-06 3-(2,3-디히드로-1h-인덴-5-일)프로판산 유도체 및 nrf2 조절제로서의 그의 용도
PCT/IB2016/057387 WO2018104766A1 (fr) 2016-12-06 2016-12-06 Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2016/057387 WO2018104766A1 (fr) 2016-12-06 2016-12-06 Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2

Publications (1)

Publication Number Publication Date
WO2018104766A1 true WO2018104766A1 (fr) 2018-06-14

Family

ID=57614404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/057387 WO2018104766A1 (fr) 2016-12-06 2016-12-06 Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2

Country Status (3)

Country Link
KR (1) KR20190088404A (fr)
CN (1) CN108779108A (fr)
WO (1) WO2018104766A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485806B2 (en) 2015-06-15 2019-11-26 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
WO2020165776A1 (fr) 2019-02-15 2020-08-20 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2
WO2020241853A1 (fr) 2019-05-31 2020-12-03 宇部興産株式会社 Dérivé de benzotriazole
US10947252B2 (en) 2018-08-20 2021-03-16 Janssen Pharmaceutica Nv Inhibitors of KEAP1-Nrf2 protein-protein interaction
US11028099B2 (en) 2016-12-15 2021-06-08 Glaxosmithkline Intellectual Property Development Limited NRF2 activators

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336A (en) 1979-12-06 1981-06-17 Glaxo Group Ltd Device for dispensing medicaments
EP0069715A1 (fr) 1981-07-08 1983-01-12 Aktiebolaget Draco Inhalateur de poudre
GB2129691A (en) 1982-10-08 1984-05-23 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265A (en) 1982-10-08 1986-07-09 Glaxo Group Ltd Pack for medicament
GB2178965A (en) 1985-07-30 1987-02-25 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2242134A (en) 1990-03-02 1991-09-25 Glaxo Group Ltd Inhalation device
US6321747B1 (en) 1997-01-08 2001-11-27 Smithkline Beecham Corporation Inhalation device
US6378519B1 (en) 1990-03-02 2002-04-30 Glaxo Group Limited Inhalation device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
WO2003061743A1 (fr) 2002-01-25 2003-07-31 Glaxo Group Limited Distributeur de medicament
WO2007012871A1 (fr) 2005-07-28 2007-02-01 Glaxo Group Limited Distributeur de médicaments
WO2007068896A1 (fr) 2005-12-12 2007-06-21 Glaxo Group Limited Distributeur à utiliser dans un appareil distributeur de médicament
WO2015092713A1 (fr) * 2013-12-18 2015-06-25 Glaxosmithkline Intellectual Property Development Limited Régulateurs de nrf2
WO2016203401A1 (fr) * 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Régulateurs de nrf2

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336A (en) 1979-12-06 1981-06-17 Glaxo Group Ltd Device for dispensing medicaments
EP0069715A1 (fr) 1981-07-08 1983-01-12 Aktiebolaget Draco Inhalateur de poudre
GB2129691A (en) 1982-10-08 1984-05-23 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265A (en) 1982-10-08 1986-07-09 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2178965A (en) 1985-07-30 1987-02-25 Glaxo Group Ltd Devices for administering medicaments to patients
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
US5035237A (en) 1985-07-30 1991-07-30 Newell Robert E Devices for administering medicaments to patients
US5860419A (en) 1990-03-02 1999-01-19 Glaxo Group Limited Inhalation device
US5590645A (en) 1990-03-02 1997-01-07 Glaxo Group Limited Inhalation device
GB2242134A (en) 1990-03-02 1991-09-25 Glaxo Group Ltd Inhalation device
US5873360A (en) 1990-03-02 1999-02-23 Glaxo Group Limited Inhalation device
US6032666A (en) 1990-03-02 2000-03-07 Glaxo Group Limited Inhalation device
US6378519B1 (en) 1990-03-02 2002-04-30 Glaxo Group Limited Inhalation device
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
US6321747B1 (en) 1997-01-08 2001-11-27 Smithkline Beecham Corporation Inhalation device
WO2003061743A1 (fr) 2002-01-25 2003-07-31 Glaxo Group Limited Distributeur de medicament
WO2007012871A1 (fr) 2005-07-28 2007-02-01 Glaxo Group Limited Distributeur de médicaments
WO2007068896A1 (fr) 2005-12-12 2007-06-21 Glaxo Group Limited Distributeur à utiliser dans un appareil distributeur de médicament
WO2015092713A1 (fr) * 2013-12-18 2015-06-25 Glaxosmithkline Intellectual Property Development Limited Régulateurs de nrf2
WO2016203401A1 (fr) * 2015-06-15 2016-12-22 Glaxosmithkline Intellectual Property Development Limited Régulateurs de nrf2

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Annals of Anatomy - Anatomischer Anzeiger", vol. 196, September 2014, pages: 268 - 277
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
"The Handbook of Pharmaceutical Additives", GOWER PUBLISHING LIMITED
"The Handbook of Pharmaceutical Excipients", THE AMERICAN PHARMACEUTICAL ASSOCIATION AND THE PHARMACEUTICAL PRESS
ALEKSUNES, L.M. ET AL., J. PHARMACOL. EXP. THER., vol. 335, 2010, pages 2 - 12
BITAR, M.S. ET AL., INVEST OPHTHALMOL. VIS. SCI., vol. 53, no. 9, 24 August 2012 (2012-08-24), pages 5806 - 5813
BOUTTEN, A. ET AL., TRENDS MOL. MED., vol. 17, 2011, pages 363 - 371
BRAIN RES., vol. 1446, pages 109 - 18
CHEN, J. ET AL., PLOS ONE, vol. 3, no. 10, 2008, pages E3367
CHO, H.Y.; KLEEBERGER, S.R., TOXICOL. APPL. PHARMACOL, vol. 244, 2010, pages 43 - 56
CHOWDHRY S. ET AL., FREE RAD. BIOL. & MED., vol. 48, 2010, pages 357 - 371
DIPALI P.K. ET AL., INDIAN J CLIN BIOCHEM., vol. 25, no. 4, October 2010 (2010-10-01), pages 388 - 392
HARVEY, C. J. ET AL., SCI. TRANSL. MED., vol. 3, 2011, pages 78RA32
KHOR,T.O. ET AL., CANCER PREV. RES. (PHILA), vol. 1, 2008, pages 187 - 191
KIM JH ET AL., J. CLIN. INVEST., vol. 124, no. 2, 3 February 2014 (2014-02-03), pages 730 - 41
LISK C. ET AL., FREE RADIC BIOL MED., vol. 63, 2013, pages 264 - 273
NOAH, T.L. ET AL., PLOS ONE, vol. 9, no. 6, 2014, pages E98671
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2013, pages 10
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2013, pages 9
PAUPE V. ET AL., PLOS ONE, vol. 4, no. 1, 2009, pages E4253
SCHAFER, M. ET AL., GENES & DEVL., vol. 24, 2010, pages 1045 - 1058
SCHIMEL ET AL., AM. J. PATHOL, vol. 178, 2011, pages 2032 - 2043
SHELTON, L.M. ET AL., KIDNEY INTERNATIONAL, 19 June 2013 (2013-06-19)
SHIH, A.Y. ET AL., J. NEUROSCI., vol. 25, 2005, pages 10321 - 10335
SHIMOZONO R. ET AL., MOLECULAR PHARMACOLOGY, vol. 84, 2012, pages 62 - 70
T. GREENE; P. WUTS: "Protecting Groups in Chemical Synthesis, 3rd ed.", 1999, JOHN WILEY & SONS

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10485806B2 (en) 2015-06-15 2019-11-26 Glaxosmithkline Intellectual Property Development Limited Nrf2 regulators
US11028099B2 (en) 2016-12-15 2021-06-08 Glaxosmithkline Intellectual Property Development Limited NRF2 activators
US10947252B2 (en) 2018-08-20 2021-03-16 Janssen Pharmaceutica Nv Inhibitors of KEAP1-Nrf2 protein-protein interaction
US11427601B1 (en) 2018-08-20 2022-08-30 Janssen Pharmaceutica Nv Inhibitors of KEAP1-Nrf2 protein-protein interaction
US11897900B2 (en) 2018-08-20 2024-02-13 Janssen Pharmaceutica Nv Inhibitors of KEAP1-Nrf2 protein-protein interaction
WO2020165776A1 (fr) 2019-02-15 2020-08-20 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2
AU2020222080B2 (en) * 2019-02-15 2022-05-19 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazepines as Nrf2 activators
AU2020222080C1 (en) * 2019-02-15 2022-09-29 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazepines as Nrf2 activators
US11945826B2 (en) 2019-02-15 2024-04-02 Glaxosmithkline Intellectual Property Development Limited Hydroxypyridoxazepines as NRF2 activators
WO2020241853A1 (fr) 2019-05-31 2020-12-03 宇部興産株式会社 Dérivé de benzotriazole
KR20220016124A (ko) 2019-05-31 2022-02-08 우베 고산 가부시키가이샤 벤조트리아졸 유도체

Also Published As

Publication number Publication date
CN108779108A (zh) 2018-11-09
KR20190088404A (ko) 2019-07-26

Similar Documents

Publication Publication Date Title
US10485806B2 (en) Nrf2 regulators
KR102675041B1 (ko) Nrf2 조절제
JP6630671B2 (ja) Ｎｒｆ２レギュレーター
WO2016203400A1 (fr) Régulateurs de nrf2
WO2018104766A1 (fr) Dérivés d'acide propanoïque 3-(2,3-dihydro-1h-inden-5-yl) et leur utilisation en tant que régulateurs de nrf2
HK40034594B (en) Nrf2 regulators
HK40034594A (en) Nrf2 regulators
BR112017027137B1 (pt) Compostos análogos de aril, composição farmacêutica compreendendo os mesmos e uso dos mesmos para o tratamento de desordens respiratórias ou não-respiratórias
HK40045853B (en) Nrf2 regulators
HK40045853A (en) Nrf2 regulators
HK1256199B (en) Nrf2 regulators
HK1245767A1 (en) Nrf2 regulators
HK1245767B (en) Nrf2 regulators

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 20187017624

Country of ref document: KR

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16819174

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16819174

Country of ref document: EP

Kind code of ref document: A1